Press releases
- Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
- Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)
- Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting
- Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
- Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
- Innovent Announces 2023 Annual Results and Business Updates
- Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)
- Innovent released the results of two clinical studies of IBI311 (an anti-IGF-1R monoclonal antibody) in oral presentations at the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024
- Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia
- Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA
More ▼
Key statistics
As of last trade Innovent Biologics Inc (6IB:MUN) traded at 4.72, -16.46% below its 52-week high of 5.65, set on Nov 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.72 |
---|---|
High | 4.72 |
Low | 4.72 |
Bid | 4.68 |
Offer | 4.76 |
Previous close | 4.64 |
Average volume | 0.00 |
---|---|
Shares outstanding | 1.62bn |
Free float | 1.51bn |
P/E (TTM) | -- |
Market cap | 61.91bn HKD |
EPS (TTM) | -0.7048 HKD |
Data delayed at least 15 minutes, as of Apr 29 2024 07:09 BST.
More ▼